Bo Rode Hansen
Directeur Général chez Genevant Sciences Corp.
Profil
Bo Rode Hansen is currently the President & Chief Executive Officer at Genevant Sciences Corp.
and a Non-Executive Director at LIfT BioSciences Ltd.
Previously, he served as the President, Chief Executive Officer & Director at Scandion Oncology A.
He also held the position of President & Chief Executive Officer at Genevant Sciences, Inc. and General Manager at Roche Innovation Center Copenhagen A.
Postes actifs de Bo Rode Hansen
| Sociétés | Poste | Début |
|---|---|---|
Genevant Sciences Corp.
 Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Directeur Général | 19/11/2018 |
LIfT BioSciences Ltd.
 LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Directeur/Membre du Conseil | 21/12/2023 |
Anciens postes connus de Bo Rode Hansen
| Sociétés | Poste | Fin |
|---|---|---|
| SCANDION ONCOLOGY A/S | Directeur Général | 31/08/2022 |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Corporate Officer/Principal | - |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Directeur Général | - |
Genevant Sciences, Inc.
 Genevant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Genevant Sciences, Inc. is a company based in Cambridge, MA that specializes in nucleic acid drug development and delivery. The company has developed lipid nanoparticle (LNP) technology and next-generation ligand conjugate technology for delivery of gene editing payloads, small interfering RNA (siRNA), and other oligonucleotide payloads. The company has a robust and expansive LNP patent estate and decades of experience and expertise in nucleic acid drug development. The company is committed to maximizing every opportunity to transform the future of human health by expanding their focus to extrahepatic tissues and cell types, such as the lung, stellate cells, and leukocytes. Genevant Sciences has built expertise in siRNA payload design and development and has more than 700 patents worldwide that they own or license. The company is open, collaborative, and entrepreneurial, and are always ready to connect with people interested in the pioneering work they do. | Directeur Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| SCANDION ONCOLOGY A/S | Health Technology |
| Entreprise privées | 4 |
|---|---|
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Health Technology |
Genevant Sciences Corp.
Genevant Sciences Corp. Pharmaceuticals: MajorHealth Technology Part of Roivant Sciences Ltd., Genevant Sciences Corp. operates as a Canadian biopharmaceutical company. The company is based in Burnaby, Canada. The CEO of the company is Bo Rode Hansen. | Health Technology |
Genevant Sciences, Inc.
Genevant Sciences, Inc. Pharmaceuticals: MajorHealth Technology Genevant Sciences, Inc. is a company based in Cambridge, MA that specializes in nucleic acid drug development and delivery. The company has developed lipid nanoparticle (LNP) technology and next-generation ligand conjugate technology for delivery of gene editing payloads, small interfering RNA (siRNA), and other oligonucleotide payloads. The company has a robust and expansive LNP patent estate and decades of experience and expertise in nucleic acid drug development. The company is committed to maximizing every opportunity to transform the future of human health by expanding their focus to extrahepatic tissues and cell types, such as the lung, stellate cells, and leukocytes. Genevant Sciences has built expertise in siRNA payload design and development and has more than 700 patents worldwide that they own or license. The company is open, collaborative, and entrepreneurial, and are always ready to connect with people interested in the pioneering work they do. | Health Technology |
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Commercial Services |